Document Detail

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization.
MedLine Citation:
PMID:  21252956     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To determine the pre-treatment ocular factors significantly associated with the visual outcome 24 months after intravitreal bevacizumab (IVB) for myopic choroidal neovascularization (mCNV).
METHODS: A total of 23 eyes of 23 patients with mCNV were treated with IVB followed by as needed therapy. The efficacy of IVB was evaluated by the best-corrected visual acuity (BCVA) at 24 months after the initial treatment. Forward stepwise multiple linear regression analyses were performed to evaluate the influence of pre-treatment factors on the BCVA and the improvement of the BCVA at 24 months.
RESULTS: The mean pre-IVB BCVA was 0.74 ± 0.30 logarithm of the minimum angle of resolution (logMAR) units, and it improved to 0.43 ± 0.31 logMAR units after 1 month (P < 0.001, paired t-test). The improvement was maintained at 24 months (0.46 ± 0.40, P < 0.005). The mean number of IVB performed during the 24 months was 1.35 ± 0.71. Forward stepwise regression analysis showed that the pre-IVB CNV size (standardized β = 0.52, P < 0.01) and BCVA (standardized β = -0.44, P < 0.05) significantly affected the visual acuity change after 24 months. The CNV size was the only factor that significantly affected the BCVA after 24 months (standardized β=0.56, P < 0.01).
CONCLUSIONS: IVB with as needed therapy for mCNV led to a rapid and sustained visual improvement. Smaller CNV size was a significant prognostic factor that predicts better visual acuity. Patients with lower pre-treatment BCVA had better visual recovery than those with better pre-treatment BCVA, however, this may be due to a ceiling/floor effect.
H Nakanishi; A Tsujikawa; Y Yodoi; Y Ojima; A Otani; H Tamura; K Yamashiro; S Ooto; N Yoshimura
Related Documents :
20102716 - Pentoxifylline does not decrease short-term mortality but does reduce complications in ...
17030176 - Utility of a new model to diagnose an alcohol basis for steatohepatitis.
18261546 - A comparison of right and left lobectomies for living donor liver transplantation: an a...
17149716 - Salvage hepatic resection after incomplete interstitial therapy for primary and seconda...
2105256 - Effect of total enteral nutrition on the short-term outcome of severely malnourished ci...
16430546 - Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine s...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-01-21
Journal Detail:
Title:  Eye (London, England)     Volume:  25     ISSN:  1476-5454     ISO Abbreviation:  Eye (Lond)     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-10     Completed Date:  2011-08-18     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  8703986     Medline TA:  Eye (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  375-81     Citation Subset:  IM    
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage,  therapeutic use*
Antibodies, Monoclonal / administration & dosage,  therapeutic use*
Antibodies, Monoclonal, Humanized
Choroidal Neovascularization / drug therapy*,  pathology
Intravitreal Injections
Middle Aged
Myopia, Degenerative / complications*
Outcome Assessment (Health Care)
Regression Analysis
Visual Acuity
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A new ocular trauma score in pediatric penetrating eye injuries.
Next Document:  Blood pressures in newborns with twin-twin transfusion syndrome.